Cancer Research UK and Cancer Research Technology are to begin phase I clinical trials of a GlaxoSmithKline anti-cancer drug.
The trials of the drug will be the third to enter Cancer Research UK’s Clinical Development Partnerships (CDP) programme, however, Glaxo’s 1070916A, which is an aurora kinase inhibitor, is the only drug which is ready to be used in patients.
The trials will take place at St James’s University Hospital in Leeds and Barts and The London’s Experimental Cancer Medicine Centre in London and will be managed by Cancer Research UK’s drug development office.
As part of the research around 30 to 40 patients with advanced solid tumours, who have had all the treatments currently available, will be tested with the new drug.
If the findings are successful then there will be an opportunity for Cancer Research UK to carry out further phase II trials.
Dr Victoria John, head of clinical partnerships at Cancer Research UK, said: “We are delighted to be working with GSK on this promising new molecule under our CDP initiative.
“This deal brings our CDP portfolio to three and the total number of new drugs in our early preclinical and clinical pipeline to over 40.”
Copyright Press Association 2009